Prognostic and predictive biomarkers in lung cancer. A review

Virchows Archiv

Volumn 464, Issue 3, 2014, Pages 347-358

  Thunnissen, Erik ^a   Van Der Oord, Kimberly ^a   Den Bakker, Michael ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Maasstad Hospital Rotterdam   (Netherlands)

Author keywords

Histology; Lung cancer; Prediction; Prognosis; Review

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; B RAF KINASE; BIOLOGICAL MARKER; DDR 2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; K RAS PROTEIN; NUT PROTEIN; PIK 3 CA PROTEIN; PROTEIN RET; ROS 1 PROTEIN; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; GENE MUTATION; HUMAN; LUNG CANCER; LUNG PARENCHYMA; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT RESPONSE;

HUMANS; LUNG NEOPLASMS; MUTATION; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84897096705     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-014-1535-4     Document Type: Short Survey

References (161)

1. Vallières E, Shepherd FA, Crowley J et al (2009) The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 4:1049-1059. doi:10.1097/JTO.0b013e3181b27799
2. Travis WD, Giroux DJ, Chansky K et al (2008) The IASLC Lung Cancer Staging Project: proposals for the inclusion of bronchopulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. J Thorac Oncol 3: 1213-1223. doi:10.1097/JTO.0b013e31818b06e3
3. Zhu C-Q, Shih W, Li ng C-H, Tsao M-S (2006) Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 59:790-800. doi:10.1136/jcp.2005.031351 (Pubitemid 44211740)
4. Kanters SDJM, Lammers J-WJ, Voest EE (1995) Molecular and biological factors in the prognosis. Eur Respir J 8:1389-1397. doi:10.1183/09031936.95. 08081389
5. Botling J, Edlund K, Lohr M et al (2013) Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin Cancer Res 19:194-204. doi:10.1158/1078-0432. CCR-12-1139
6. Van Meerbeeck JP, Fennell DA, De Ruysscher DKM (2011) Small-cell lung cancer. Lancet 378:1741-1755. doi:10.1016/S0140-6736(11)60165-7
7. Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551. doi:10.1200/JCO.2007.15.0375
8. NSCLC Meta-Analyses Collaborative Group (2008) Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 26:4617-4625. doi:10.1200/JCO.2008. 17.7162
9. Vansteenkiste J, De Ruysscher D, Eberhardt WEE et al (2013) Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:1-10. doi:10.1093/annonc/mdt241
10. Soria J-C, Mauguen A, Reck M et al (2013) Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 24:20-30. doi:10.1093/annonc/mds590
11. Lima ABC, Macedo LT, Sasse AD (2011) Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 6:e22681. doi:10.1371/journal.pone.0022681
12. Travis W, Brambilla E, Muller-Hermelink H (2004) WHO classification of tumours, pathology and genetics: tumors of the lung, pleura thymus and heart. IARC Press, Lyon
13. Travis WD, Brambilla E, Noguchi M et al (2011) International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 6:244-285. doi:10.1097/JTO.0b013e318206a221
14. Travis WD, Brambilla E, Noguchi M et al (2012) Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification. Arch Pathol Lab Med. doi:10.5858/arpa.2012- 0263-RA
15. Thunnissen E, Boers E, Heideman DA et al (2012) Correlation of immunohistochemical staining p63 and TTF-1 with EGFR and K-Virchows ras mutational spectrum and diagnostic reproducibility in non small cell lung carcinoma. Virchows Arch. doi:10.1007/s00428-012-1324-x
16. Bishop JA, Teruya-Feldstein J, Westra WH et al (2012) p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 25:405-415. doi:10.1038/modpathol.2011.173
17. Nonaka D (2012) A study of DeltaNp63 expression in lung non-small cell carcinomas. Am J Surg Pathol 36:895-899. doi:10.1097/PAS.0b013e3182498f2b
18. Rekhtman N, Paik PK, Arcila ME et al (2012) Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 18:1167-1176. doi:10.1158/1078-0432.CCR-11-2109.Clarifying
19. Liu Y, Yin T-J, Zhou R et al (2013) Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis. Cancer Chemother Pharmacol. doi:10.1007/s00280-013-2299-2
20. Nicolson MC, Fennell DA, Ferry D et al (2013) Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial. J Thorac Oncol 8:930-939. doi:10.1097/JTO.0b013e318292c500
21. Olaussen KA, Dunant A, Fouret P et al (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983-991. doi:10.1056/NEJMoa060570 (Pubitemid 44343542)
22. Wachters FM, Wong LSM, Timens W et al (2005) ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer 50:211-219. doi:10.1016/j.lungcan.2005.06.013 (Pubitemid 41427896)
23. Vilmar AC, Santoni-Rugiu E, Sørensen JB (2010) ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol 21:1817-1824. doi:10.1093/annonc/mdq053
24. Reynolds C, Obasaju C, Schell MJ et al (2009) Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 27:5808-5815. doi:10.1200/JCO.2009.21.9766
25. Booton R, Ward T, Ashcroft L et al (2007) ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol 2:902-906. doi:10.1097/JTO.0b013e318155a637 (Pubitemid 47511592)
26. Cobo M, Isla D, Massuti B et al (2007) Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 25:2747-2754. doi:10.1200/JCO.2006.09.7915 (Pubitemid 47123183)
27. Bepler G, Williams C, Schell MJ et al (2013) Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 31:2404-2412. doi:10.1200/JCO.2012.46.9783
28. Maus MKH, Mack PC, Astrow SH et al (2013) Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy. J Thorac Oncol 8:582-586. doi:10.1097/JTO. 0b013e318287c3c5
29. Jakobsen JN, Santoni-Rugiu E, Ravn J, Sørensen JB (2013) Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer. Eur J Cancer 49:2494-2503. doi:10.1016/j.ejca.2013.04.003
30. Vilmar A, Garcia-Foncillas J, Huarriz M et al (2012)RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC. Lung Cancer 75:306-312. doi:10.1016/j.lungcan.2011.08.016
31. Mok TS, Wu Y-L, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957. doi:10.1056/NEJMoa0810699
32. Sequist LV, Yang JC-H, Yamamoto N et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients withmetastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327-3334. doi:10.1200/JCO.2012.44.2806
33. Zhou C, Wu Y-L, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735-742. doi:10.1016/S1470-2045(11) 70184-X
34. Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121-128. doi:10.1016/S1470-2045(09)70364-X
35. Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239-246. doi:10.1016/S1470-2045(11)70393-X
36. Shaw AT, Kim D-W, Nakagawa K et al (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:130601060020006. doi:10.1056/NEJMoa1214886
37. Govindan R, Ding L, Griffith M et al (2013) Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150:1121-1134. doi:10.1016/j.cell.2012.08.024.GENOMIC
38. Imielinski M, Berger AH, Hammerman PS et al (2013) Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150:1107-1120. doi:10.1016/j.cell.2012.08.029.Mapping
39. Ding L, Getz G, Wheeler DA et al (2009) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069-1075. doi:10.1038/nature07423. Somatic
40. Lindeman NI, Cagle PT, Beasley MB et al (2013) Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Patho. Arch Pathol Lab Med 137:828-860. doi:10.5858/arpa.2012-0720-OA
41. Lee CK, Brown C, Gralla RJ et al (2013) Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 105:595-605. doi:10.1093/jnci/djt072
42. Gahr S, Stoehr R, Geissinger E et al (2013) EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. Br J Cancer. doi:10.1038/bjc.2013.511
43. Dearden S, Stevens J, Wu Y-L, Blowers D (2013) Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol 24:2371-2376. doi:10.1093/annonc/mdt205
44. Thunnissen E, Kerr KM, Herth FJ et al (2012) The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer 76:1-18. doi:10.1016/j.lungcan.2011.10.017
45. Brevet M, Arcila M, Ladanyi M (2010) Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 12:169-176. doi:10.2353/jmoldx.2010. 090140
46. Yu J, Kane S, Wu J et al (2009) Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 15:3023-3028. doi:10.1158/1078-0432.CCR-08-2739
47. Simonetti S, Molina MA, Queralt C et al (2010) Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. J Transl Med 8:135. doi:10.1186/1479-5876-8-135
48. Kawahara A, Yamamoto C, Nakashima K et al (2010) Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Clin Cancer Res 16:3163-3170. doi:10.1158/1078-0432.CCR-09-3239
49. Kitamura A, Hosoda W, Sasaki E et al (2010) Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer. Clin Cancer Res 16: 3349-3355. doi:10.1158/1078-0432.CCR-10-0129
50. Kawahara A, Taira T, Azuma K et al (2012) A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer. Lung Cancer 78:39-44. doi:10.1016/j.lungcan.2012.07.002
51. Jiang G, Fan C, Zhang X et al (2013) Ascertaining an appropriate diagnostic algorithm using EGFR mutation-specific antibodies to detect EGFR status in non-small-cell lung cancer. PLoS One 8: e59183. doi:10.1371/journal. pone.0059183
52. Sequist LV, Waltman BA, Dias-santagata D et al (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:75ra26. doi:10.1126/scitranslmed.3002003.Genotypic
53. Zhang Z, Lee JCJ, Lin L et al (2013) Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44:852-860. doi:10.1038/ng.2330.Activation
54. Wang S, Takayama K, Tanaka K, Takeshita M, Nakagaki N, Ijichi K, Li H, Nakanishi Y (2013) Nicotine induces resistance to epidermal growth factor receptor tyrosine kinase inhibitor by α1 nicotinic acetylcholine receptor-mediated activation in PC9 cells. J Thorac Oncol 8(6):719-725. doi:10.1097/JTO.0b013e31828b51d4
55. Terai H, Soejima KN, Yasuda H et al (2013) Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC cells. Mol Cancer Res. doi:10.1158/1541-7786.MCR-12-0652
56. Ware KE, Hinz TK, Kleczko E et al (2013) A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis 2:e39. doi:10.1038/oncsis.2013.4
57. Popat S, Wotherspoon A, Nutting CM et al (2013) Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma. Lung Cancer 80:1-4. doi:10.1016/j.lungcan.2012.12.019
58. Van Riel S, Thunnissen E, Heideman D et al (2012) A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation. Ann Oncol 23:3188-3189. doi:10.1093/annonc/mds525
59. Thunnissen E, Bubendorf L, Dietel M et al (2012) EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch 461:245-257. doi:10.1007/s00428-012-1281-4
60. Conklin CMJ, Craddock KJ, Have C et al (2013) Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol 8:45-51. doi:10.1097/JTO.0b013e318274a83e
61. Mino-Kenudson M, Chirieac LR, Law K et al (2010) A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 16:1561-1571. doi:10.1158/1078-0432.CCR-09-2845
62. Yi ES, Boland JM, Maleszewski JJ et al (2011) Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J Thorac Oncol 6:459-465. doi:10.1097/JTO.0b013e318209edb9
63. Wallander ML, Geiersbach KB, Tripp SR, Layfield LJ (2012) Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small. Arch Pathol Lab Med 136:796-803. doi:10.5858/arpa.2011-0321-OA
64. Park HS, Lee JK, Kim D-W et al (2012) Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer 77: 288-292. doi:10.1016/j.lungcan.2012.03.004
65. + lung adenocarcinoma. J Thorac Oncol 7:90-97. doi:10.1097/JTO.0b013e31823c5c32
66. Paik JH, Choi C-M, Kim H et al (2012) Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer 76:403-409. doi:10.1016/j.lungcan.2011.11.008
67. McLeer-Florin A, Moro-Sibilot D, Melis A et al (2012) Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J Thorac Oncol 7:348-354. doi:10.1097/JTO. 0b013e3182381535
68. Mino-Kenudson M, Mark EJ (2011) Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ hybridization in non-small cell lung cancer. Arch Pathol Lab Med 135:655-664. doi:10.1043/2011-0029-RAI.1
69. Kim H, Yoo S-B, Choe J-Y et al (2011) Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol 6:1359-1366. doi:10.1097/JTO.0b013e31821cfc73
70. Just P-A, Cazes A, Audebourg A et al (2012) Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: a comprehensive study of Caucasian non-smokers. Lung Cancer 76:309-315. doi:10.1016/j.lungcan.2011.11.004
71. Firat S, Pleister A, Byhardt R et al (2012) Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma. Ann Oncol 23:1738-1743. doi:10.1093/annonc/mdr535
72. Wu Y-C, Chang I-C, Wang C-L et al (2013) Comparison of IHC, FISH and RT-PCRmethods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. PLoS One 8: e70839. doi:10.1371/journal.pone.0070839
73. Han X-H, Zhang N-N, Ma L et al (2013) Immunohistochemistry reliably detects ALK rearrangements in patients with advanced non-small-cell lung cancer. Virchows Arch. doi:10.1007/s00428-013-1472-7
74. Takamochi K, Takeuchi K, Hayashi T et al (2013) A rational diagnostic algorithm for the identification of ALK rearrangement in lung cancer: a comprehensive study of surgically treated Japanese patients. PLoS One 8:e69794. doi:10.1371/journal.pone.0069794
75. Peled N, Palmer G, Hirsch FR et al (2012) Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol 7(9):e14-e16
76. Sun J-M, Choi Y-L, Won J-K et al (2012) A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive nd FISH-negative ALK. J Thorac Oncol 7(12):e36-e38
77. Sholl LM, Weremowicz S, Gray SWet al (2013) Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J Thorac Oncol 8:322-328. doi:10.1097/JTO.0b013e31827db604
78. Sadiq AA, Salgia R (2013) MET as a possible target for non-small-cell lung cancer. J Clin Oncol 31:1089-1096. doi:10.1200/JCO.2012.43.9422
79. Bergethon K, Shaw AT, Ou S-HI et al (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863-870. doi:10.1200/JCO.2011.35.6345
80. Marchetti A, Felicioni L, Malatesta S et al (2011) Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 29:3574-3579. doi:10.1200/JCO.2011.35.9638
81. Oxnard GR, Binder A, Jänne PA (2013) New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol 31:1097-1104. doi:10.1200/JCO.2012.42. 9829
82. Mazières J, Peters S, Lepage B et al (2013) Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 31:1997-2003. doi:10.1200/JCO.2012.45.6095
83. Pirker R, Pereira JR, von Pawel J et al (2012) EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data fromthe phase 3 FLEX study. Lancet Oncol 13:33-42. doi:10.1016/S1470-2045(11)70318-7
84. Reungwetwattana T, Molina JR, Mandrekar SJ et al (2012) Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study. J Thorac Oncol 7:919-922. doi:10.1097/JTO.0b013e31824de0d6
85. Ohashi K, Sequist LV, Arcila ME et al (2013) Characteristics of lung cancers harboring NRAS mutations. Clin Cancer Res 19:2584-2591. doi:10.1158/1078-0432.CCR-12-3173
86. Martin P, Leighl NB, Tsao M-S, Shepherd FA (2013) KRAS mutations as prognostic and predictive markers in non-small cell lung cancer. J Thorac Oncol 8:530-542. doi:10.1097/JTO.0b013e318283d958
87. Vaishnavi A, Capelletti M, Le AT et al (2013) Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. doi:10.1038/nm.3352
88. Hammerman PS, Sos ML, Ramos AH et al (2011) Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 1:78-89. doi:10.1158/2159-8274.CD-11-0005
89. Ren M, Hong M, Liu G et al (2013) Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1. Oncol Rep 29:2181-2190. doi:10.3892/or.2013.2386
90. Bellezza G, Del Sordo R, Colella R et al (2013) Co-expression of receptors of the HER family correlates with clinical outcome in non-small cell lung cancer (NSCLC). Virchows Arch. doi:10.1007/s00428-013-1445-x
91. Liu L, Shao X, Gao W et al (2010) The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer. J Thorac Oncol 5:1922-1932. doi:10.1097/JTO.0b013e3181f26266
92. Shigematsu H, Takahashi T, Nomura M et al (2005) Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65:1642-1646. doi:10.1158/0008-5472.CAN-04-4235 (Pubitemid 40478587)
93. Buttitta F, Barassi F, Fresu G et al (2006) Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer 119:2586-2591. doi:10.1002/ijc.22143 (Pubitemid 44691311)
94. Stephens P, Hunter C, Bignell Get al (2004) Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431:525-526. doi:10.1038/431525b
95. Arcila ME, Chaft JE, Nafa K et al (2012) Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res 18:4910-4918. doi:10.1158/1078-0432. CCR-12-0912
96. Ross HJ, Blumenschein GR, Aisner J et al (2010) Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin Cancer Res 16:1938-1949. doi:10.1158/1078-0432.CCR-08-3328
97. Cardarella S, Ogino A, Nishino M et al (2013) Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 19:4532-4540. doi:10.1158/1078-0432.CCR-13-0657
98. Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-954. doi:10.1038/nature00766 (Pubitemid 34716871)
99. Sasaki H, Shimizu S, Tani Y et al (2013) Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in Japanese lung adenocarcinoma. Lung Cancer 82:51-54. doi:10.1016/j.lungcan.2013.06.014
100. Gautschi O, Pauli C, Strobel K et al (2012) A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol 7:e23-e24. doi:10.1097/JTO.0b013e3182629903
101. Peter S, Michielin O, Zimmermann S (2013) Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J Clin Oncol 1(20):e341-e344
102. Kohno T, Ichikawa H, Totoki Y et al (2012) KIF5B-RET fusions in lung adenocarcinoma. Nat Med 18:375-377. doi:10.1038/nm.2644
103. Takeuchi K, Soda M, Togashi Yet al (2012) RET, ROS1 and ALK fusions in lung cancer. Nat Med 18:378-381. doi:10.1038/nm.2658
104. Li F, Feng Y, Fang R et al (2012) Identification of RET gene fusion by exon array analyses in "pan-negative" lung cancer from never smokers. Cell Res 22:928-931. doi:10.1038/cr.2012.27
105. Wang R, Hu H, Pan Y et al (2012) RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 30:4352-4359. doi:10.1200/JCO.2012.44.1477
106. Drilon A, Wang LL, Hasanovic A et al (2013) Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. doi:10.1158/2159-8290.CD-13-0035
107. Seo J-S, Ju YS, Lee W-C et al (2012) The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 22:2109-2119. doi:10.1101/gr.145144.112
108. Suehara Y, Arcila M, Wang L et al (2012) Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin Cancer Res 18:6599-6608. doi:10.1158/1078-0432.CCR-12-0838
109. Lipson D, Capelletti M, Yelensky R et al (2012) Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 18:382-384. doi:10.1038/nm.2673
110. Sasaki H, Shimizu S, Tani Y et al (2012) RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer. Cancer Med 1:68-75. doi:10.1002/cam4.13
111. Suzuki M, Makinoshima H, Matsumoto S et al (2013) Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo. Cancer Sci. doi:10.1111/cas.12175
112. Gautschi O, Zander T, Keller FA et al (2013) A patient with lung adenocarcinoma and RET fusion treated with vandetanib. J Thorac Oncol 8:e43-e44. doi:10.1097/JTO.0b013e31828a4d07
113. Gu T-L, Deng X, Huang F et al (2011) Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 6:e15640. doi:10.1371/journal.pone.0015640
114. Rimkunas VM, Crosby KE, Li D et al (2012) Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res 18:4449-4457. doi:10.1158/1078-0432.CCR-11-3351
115. Rikova K, Guo A, Zeng Q et al (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190-1203. doi:10.1016/j.cell.2007.11.025 (Pubitemid 350235027)
116. Matsuura S, Shinmura K, Kamo T et al (2013) CD74-ROS1 fusion transcripts in resected non-small cell lung carcinoma. Oncol Rep 30: 1675-1680. doi:10.3892/or.2013.2630
117. Kim HR, Lim SM, Kim HJ et al (2013) The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Ann Oncol 24:2364-2370. doi:10.1093/annonc/mdt220
118. Yoshida A, Kohno T, Tsuta K et al (2013) ROS1-rearranged lung cancer. A clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol 37:554-562
119. Cai W, Li X, Su C et al (2013) ROS1 fusions in Chinese patients with non-small-cell lung cancer. Ann Oncol 24:1822-1827. doi:10.1093/annonc/mdt071
120. Davies KD, Le AT, Theodoro MF et al (2012) Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res 18:4570-4579. doi:10.1158/1078-0432.CCR-12-0550
121. Riess JW, Padda SK, Bangs CD et al (2013) A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non-small-cell lung cancer patients harboring ROS1 gene rearrangements. Clin Lung Cancer 14:592-595. doi:10.1016/j.cllc.2013.04.008
122. Awad MM, Katayama R, McTigue M et al (2013) Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med 368:2395-2401. doi:10.1056/NEJMoa1215530
123. Wiesweg M, Ting S, Reis H et al (2013) Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a comprehensive cancer center. Eur J Cancer. doi:10.1016/j.ejca.2013.06.014
124. Pitini V, Arrigo C, Di Mirto C et al (2013) Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia. Lung Cancer 82:171-172. doi:10.1016/j.lungcan. 2013.07.004
125. Khurshid H, Dipetrillo T, Ng T et al (2012) A phase I study of dasatinib with concurrent chemoradiation for stage III non-small cell lung cancer. Front Oncol 2:56. doi:10.3389/fonc.2012.00056
126. Cardarella S, Ortiz TM, Joshi VA et al (2012) The introduction of systematic genomic testing for patients with non-small-cell lung cancer. J Thorac Oncol 7:1767-1774. doi:10.1097/JTO.0b013e3182745bcb
127. Kawano O, Sasaki H, Endo K et al (2006) PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 54:209-215. doi:10.1016/j.lungcan. 2006.07.006 (Pubitemid 44764916)
128. Kawano O, Sasaki H, Okuda K et al (2007) PIK3CA gene amplification in Japanese non-small cell lung cancer. Lung Cancer 58: 159-160. doi:10.1016/j.lungcan.2007.06.020 (Pubitemid 47379973)
129. Spoerke JM, O'Brien C, Huw L et al (2012) Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res 18:6771-6783. doi:10.1158/1078-0432.CCR-12-2347
130. Chaft JE, Arcila ME, Paik PK et al (2012) Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol Cancer Ther 11:485-491. doi:10.1158/1535-7163.MCT-11-0692
131. Zhang L, Shi L, Zhao X et al (2013) PIK3CA gene mutation associated with poor prognosis of lung adenocarcinoma. Onco Targets Ther 6:497-502. doi:10.2147/OTT.S41643
132. Yu J, Bai H, Wang Z et al (2013) PIK3CA mutation in Chinese patients with lung squamous cell carcinoma. Chin J Cancer Res 25: 416-422. doi:10.3978/j.issn.1000-9604.2013.08.03
133. Weiss J, Sos ML, Seidel D et al (2010) Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2:62ra93. doi:10.1126/scitranslmed. 3001451
134. Heist RS, Mino-Kenudson M, Sequist LV et al (2012) FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol 7:1775-1780. doi:10.1097/JTO.0b013e31826aed28
135. Tran TN, Selinger CI, Kohonen-Corish MRJ et al (2013) Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer. Lung Cancer 81: 462-467. doi:10.1016/j.lungcan.2013. 05.015
136. Kohler LH, Mireskandari M, Knösel T et al (2012) FGFR1 expression and gene copy numbers in human lung cancer. Virchows Arch 461:49-57. doi:10.1007/s00428-012-1250-y
137. Schildhaus H-U, Heukamp LC, Merkelbach-Bruse S et al (2012) Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod Pathol 25:1473-1480. doi:10.1038/modpathol.2012.102
138. Gadgeel SM, Chen W, Cote ML et al (2013) Fibroblast growth factor receptor 1 amplification in non-small cell lung cancer by quantitative real-time PCR. PLoS One 8:e79820. doi:10.1371/journal.pone.0079820
139. Dutt A, Ramos AH, Hammerman PS et al (2011) Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 6:e20351. doi:10.1371/journal.pone.0020351
140. Kim HR, Kim DJ, Kang DR et al (2013) Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. J Clin Oncol 31:731-737. doi:10.1200/JCO.2012.43.8622
141. Craddock KJ, Ludkovski O, Sykes J et al (2013) Prognostic value of fibroblast growth factor receptor 1 gene locus amplification in resected lung squamous cell carcinoma. J Thorac Oncol 8:1371-1377
142. Preusser M, Berghoff AS, Berger W et al (2013) High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer. Lung Cancer 1:1-7. doi:10.1016/j.lungcan.2013.10.004
143. Sun W, Song L, Ai T et al (2013) Prognostic value of MET, cyclin D1 and MET gene copy number in non-small cell lung cancer. J Biomed Res 27:220-230. doi:10.7555/JBR.27.20130004
144. Wang S, An T, Duan J et al (2013) Alterations in EGFR and related genes following neo-adjuvant chemotherapy in Chinese patients with non-small cell lung cancer. PLoS One 8:e51021. doi:10.1371/journal.pone.0051021
145. Cully M, You H, Levine AJ, Mak TW (2006) Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6:184-192. doi:10.1038/nrc1819 (Pubitemid 43292562)
146. Buckingham L, Penfield Faber L, Kim A et al (2010) PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer 126:1630-1639. doi:10.1002/ijc.24896
147. Jin G, Kim MJ, Jeon H-S et al (2010) PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer 69:279-283. doi:10.1016/j.lungcan.2009.11.012
148. Marsit CJ, Zheng S, Aldape K et al (2005) PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol 36:768-776. doi:10.1016/j.humpath.2005.05.006 (Pubitemid 41112032)
149. Cumberbatch M, Tang X, Beran G et al (2013) Identification of a subset of human non-small cell lung cancer patients with high PI3Kβ and low PTEN expression, more prevalent in SCC. Clin Cancer Res. doi:10.1158/1078-0432.CCR- 13-1638
150. Lee AC, Kwong YI, Fu KH et al (1993) Disseminated mediastinal carcinoma with chromosomal translocation (15;19). A distinctive clinicopathologic syndrome. Cancer 72:2273-2276 (Pubitemid 23280160)
151. Kubonishi I, Takehara N, Iwata J et al (1991) Novel t(15;19)(q15;p13) chromosome abnormality in a thymic carcinoma. Cancer Res 51:3327-3328
152. Kees UR, Mulcahy MT, Willoughby ML (1991) Intrathoracic carcinoma in an 11-year-old girl showing a translocation t(15;19). Am J Pediatr Hematol Oncol 13:459-464
153. Evans AG, French CA, Cameron MJ et al (2012) Pathologic characteristics of NUT midline carcinoma arising in the mediastinum. Am J Surg Pathol 36:1222-1227. doi :10.1097/PAS.0b013e318258f03b
154. Bauer DE, Mitchell CM, Strait KM et al (2012) Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res 18:5773-5779. doi:10.1158/1078-0432.CCR-12-1153
155. Schwartz BE, Hofer MD, Lemieux ME et al (2011) Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res 71:2686-2696. doi:10.1158/0008-5472.CAN-10-3513
156. Clauditz TS, Gontarewicz A, Wang C-J et al (2012) 11q21 rearrangement is a frequent and highly specific genetic alteration in mucoepidermoid carcinoma. Diagn Mol Pathol 21:134-137. doi:10.1097/PDM.0b013e318255552c
157. Von Holstein SL, Fehr A, Heegaard S et al (2012) CRTC1-MAML2 gene fusion in mucoepidermoid carcinoma of the lacrimal gland. Oncol Rep 27:1413-1416. doi:10.3892/or.2012.1676
158. Fehr A, Löning T, Stenman G (2011)Mammary analogue secretory carcinoma of the salivary glands with ETV6-NTRK3 gene fusion. Am J Surg Pathol 35:1600-1602. doi:10.1097/PAS.0b013e31822832c7
159. Stenman G (2013) Fusion oncogenes in salivary gland tumors: molecular and clinical consequences. Head Neck Pathol 7(Suppl 1):S12-S19. doi:10.1007/s12105-013-0462-z
160. Connor A, Perez-Ordoñez B, Shago M et al (2012) Mammary analog secretory carcinoma of salivary gland origin with the ETV6 gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrumof a recently described entity. Am J Surg Pathol 36:27-34. doi:10.1097/PAS.0b013e318231542a
161. Skálová A, Vanecek T, Sima R et al (2010) Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol 34:599-608. doi:10.1097/PAS.0b013e3181d9efcc